Immunoglobulin Fab Fragments
"Immunoglobulin Fab Fragments" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.
| Descriptor ID |
D007140
|
| MeSH Number(s) |
D12.644.541.500.650 D12.776.124.486.485.680.650 D12.776.124.790.651.680.650 D12.776.377.715.548.680.650
|
| Concept/Terms |
Immunoglobulin Fab Fragments- Immunoglobulin Fab Fragments
- Fab Fragments, Immunoglobulin
- Immunoglobulins, Fab Fragment
- Fab Fragment Immunoglobulins
- Fragment Immunoglobulins, Fab
- Immunoglobulin Fab Fragment
- Fab Fragment, Immunoglobulin
- Fab Immunoglobulin Fragments
- Immunoglobulin Fragments, Fab
- Fab Fragments
- Immunoglobulins, Fab
|
Below are MeSH descriptors whose meaning is more general than "Immunoglobulin Fab Fragments".
Below are MeSH descriptors whose meaning is more specific than "Immunoglobulin Fab Fragments".
This graph shows the total number of publications written about "Immunoglobulin Fab Fragments" by people in this website by year, and whether "Immunoglobulin Fab Fragments" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunoglobulin Fab Fragments" by people in Profiles.
-
RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol. Arthritis Care Res (Hoboken). 2011 Aug; 63(8):1142-9.
-
Intra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke: an open-label, dose-ranging, phase I study. Neurosurgery. 2006 Oct; 59(4):789-96; discussion 796-7.
-
Are we moving forward in the biological treatment of Crohn's disease? Time will tell. Inflamm Bowel Dis. 2006 Feb; 12(2):147-9.
-
C-reactive protein is involved in natural killer cell-mediated lysis but does not mediate effector-target cell recognition. Immunology. 1987 May; 61(1):93-9.